

Special Issue

Genitourinary Cancers: From Molecular Pathogenesis to Precision Diagnosis and Therapy

Message from the Guest Editors

This Special Issue, “Genitourinary Cancers: From Molecular Pathogenesis to Precision Diagnosis and Therapy”, will mainly focus on the integration of pathophysiology, diagnostic innovation, and therapeutic advances for prostate, bladder, renal, and testicular malignancies. Until a few years ago, the treatment of genitourinary tumors relied primarily on surgery, cytotoxic chemotherapy, and radiation. Recently, targeted therapies, immune checkpoint inhibitors, and PARP inhibitors have transformed clinical outcomes, yet drug resistance and disease recurrence remain critical challenges. Investigators have started to realize that a deeper understanding of tumor pathobiology, coupled with multi-omics and AI-driven diagnostics, is essential in developing next-generation precision therapies and overcoming therapeutic resistance. We cordially invite authors in this field to submit original research or review articles pertaining to this important and rapidly progressing field of biomedicine.

Guest Editors

Dr. Qi-Dong Xia

Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Dr. Jian-Xuan Sun

Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Deadline for manuscript submissions

31 January 2027



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/262242

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).